113
Views
0
CrossRef citations to date
0
Altmetric
Diabetes

Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression

ORCID Icon, , , , , , ORCID Icon, , , & show all
Pages 1103-1121 | Received 26 Dec 2023, Accepted 31 May 2024, Published online: 11 Jun 2024
Supplemental material

Supplemental Material

Download MS Word (11.9 KB)

Supplementary table 1.PRISMA_2020_checklist.docx

Download MS Word (30.5 KB)

Supplementary figure 1 PRISMA diagram.docx

Download MS Word (47.5 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.